PDS Biotechnology Corporation (PDSB) vs TransMedics Group, Inc. (TMDX)
A side-by-side comparison of PDS Biotechnology Corporation and TransMedics Group, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of August 30, 2026. Differences are shown without an overall score or investment verdict.
PDSB
PDS Biotechnology Corporation
$0.21HealthcareAt close: Aug 28, 2026, 4:00 PM ET
TMDX
TransMedics Group, Inc.
$88.43HealthcareAt close: Aug 28, 2026, 4:00 PM ET
Total return — PDSB vs TMDX
growth of $100 · dividends reinvested · last 7yPDSB -96.6% (-38.2%/yr)TMDX +295.5% (+21.7%/yr)TMDX compounded faster over this window
Log scale — wide-divergence pair
PDSB TMDX
PDSB vs TMDX: by the numbers
- •TMDX is the larger company ($3.06B vs $12M market cap).
- •TMDX is profitable (22.69% net margin) while PDSB runs a net loss (0.00%).
Metrics side by side
Valuation
| Metric | PDSB | TMDX |
|---|---|---|
| P/E ratio | N/A | 22.91 |
| Forward P/E | N/A | 59.11 |
| P/S ratio | N/A | 5.39 |
| P/B ratio | 3.45 | 6.95 |
| EV / EBITDA | 0.02 | 33.85 |
| FCF yield | N/A | 2.20% |
Profitability
| Metric | PDSB | TMDX |
|---|---|---|
| Gross margin | 0.00% | 58.69% |
| Operating margin | 0.00% | 12.21% |
| Net margin | 0.00% | 22.69% |
| ROE | -372.85% | 29.28% |
| ROIC | -3699.99% | 5.87% |
Growth (annualized)
| Metric | PDSB | TMDX |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 86.12% |
| Total return CAGR (5Y) | -57.05% | 22.62% |
Frequently asked
- Is PDSB or TMDX more profitable?
- TMDX runs the higher net margin — PDSB at 0.00% versus TMDX at 22.69%.
- How have PDSB and TMDX total returns compared?
- Over the past 5 years, PDSB delivered -49.05% and TMDX delivered 22.62% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
TransMedics P/E ratioPDS Biotechnology ROETransMedics ROEPDS Biotechnology operating marginTransMedics operating marginPDS Biotechnology revenue growthTransMedics revenue growthPDS Biotechnology free cash flowTransMedics free cash flow
PDS Biotechnology & TransMedics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified August 30, 2026.